193 related articles for article (PubMed ID: 37122707)
21. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
22. Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.
Mews EA; Beckmann P; Patchava M; Wang Y; Largaespada DA; Wagner CR
ACS Nano; 2022 Aug; 16(8):12185-12201. PubMed ID: 35876221
[TBL] [Abstract][Full Text] [Related]
23. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
24. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
25. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
26. T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.
Sun X; Yu Y; Ma L; Xue X; Gao Z; Ma J; Zhang M
Invest New Drugs; 2020 Jun; 38(3):722-732. PubMed ID: 31267380
[TBL] [Abstract][Full Text] [Related]
27. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
[TBL] [Abstract][Full Text] [Related]
28. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
29. B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.
Chen Q; Wang J; Chen W; Zhang Q; Wei T; Zhou Y; Xu X; Bai X; Liang T
Cancer Sci; 2019 Feb; 110(2):530-539. PubMed ID: 30548441
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
[TBL] [Abstract][Full Text] [Related]
31. Co-deficiency of B7-H3 and B7-H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer.
Si S; Wang L; Cao H; Xu Y; Zhan Q
BMC Cancer; 2022 Feb; 22(1):211. PubMed ID: 35219310
[TBL] [Abstract][Full Text] [Related]
32. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
[TBL] [Abstract][Full Text] [Related]
33. Aberrant expression of B7-H3 in gastric adenocarcinoma promotes cancer cell metastasis.
Dai W; Shen G; Qiu J; Zhao X; Gao Q
Oncol Rep; 2014 Nov; 32(5):2086-92. PubMed ID: 25120098
[TBL] [Abstract][Full Text] [Related]
34. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
35. The role of B7-H3 in tumors and its potential in clinical application.
Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
[TBL] [Abstract][Full Text] [Related]
36. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
[TBL] [Abstract][Full Text] [Related]
37. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma.
Zhao J; Meng Z; Xie C; Yang C; Liu Z; Wu S; Wang B; Fan P; Jin X; Wu H
Int J Biochem Cell Biol; 2019 Mar; 108():84-91. PubMed ID: 30664982
[TBL] [Abstract][Full Text] [Related]
38. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
39. Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody.
Liu X; Zhelev D; Adams C; Chen C; Mellors JW; Dimitrov DS
Transl Oncol; 2021 Dec; 14(12):101232. PubMed ID: 34601396
[TBL] [Abstract][Full Text] [Related]
40. Gastric Carcinomas with Stromal B7-H3 Expression Have Lower Intratumoural CD8+ T Cell Density.
Ulase D; Behrens HM; Krüger S; Zeissig S; Röcken C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
